Back

Title
  • Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View
Creator
    • Bando, Hiroshi
Rights
  • © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Subject
  • other Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
  • other Canagliflozin Cardio-Vascular Assessment Study (CANVAS)
  • other Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)
  • other Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58
  • other The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study
Description
  • Other Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.
Publisher Asploro
Date
    Issued2020-01-30
Language
  • eng
Resource Type journal article
Version Type VoR
Identifier URI http://repo.lib.tokushima-u.ac.jp/114800
Relation
  • isIdenticalTo DOI https://doi.org/10.36502/2020/droa.6156
Journal
  • Diabetes Research : Open Access 2(S1), 9-13
File
Oaidate 2020-06-05